Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 18/20 | 0.85 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.85 |
| ▸ | TTR | P02766 | 1/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthogalenol SCHEMBL4837282 | 0.92 | PDPK1 (0.84) | ABCB1PDPK1TTRALOX5MEN1 | |
| Xanthohumol SCHEMBL30169731 | 0.92 | PDPK1 (1.00) | ABCB1PDPK1TTRALOX5MEN1 | |
| Xanthohumol SCHEMBL738122 | 0.92 | PDPK1 (1.00) | ABCB1PDPK1TTRALOX5MEN1 | |
| Xanthohumol SCHEMBL143683 | 0.92 | PDPK1 (1.00) | ABCB1PDPK1TTRALOX5MEN1 | |
| SCHEMBL5519601 | 0.92 | ABCB1 (1.00) | ABCB1PDPK1TTRALOX5 | |
| Xanthogalenol SCHEMBL30259154 | 0.92 | PDPK1 (0.84) | ABCB1PDPK1TTRALOX5MEN1 | |
| Xanthogalenol SCHEMBL4837290 | 0.92 | PDPK1 (0.84) | ABCB1PDPK1TTRALOX5MEN1 | |
| SCHEMBL5519605 | 0.92 | ABCB1 (1.00) | ABCB1PDPK1TTRALOX5 | |
| SCHEMBL17585476 | 0.92 | ABCB1 (0.84) | ABCB1PDPK1TTRALOX5MEN1 | |
| SCHEMBL16166208 | 0.91 | ABCB1 (1.00) | ABCB1PDPK1TTRALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2019-02-14 | — | — | US | claimed |
| US-20150283098-A1 | PRENYLATED CHALCONE FORMULATION FOR THE TREATMENT OF BEES | BIOACTIVE-TECH SP Z.O.O. (PL) | 2015-10-08 | — | — | US | claimed |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2015-07-30 | — | — | US | claimed |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | US | claimed |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110207697-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL, LLC (US) | 2011-08-25 | — | — | US | claimed |
| JP-2011513308-A | — | — | 2011-04-28 | — | — | JP | claimed |
| US-20110086815-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | claimed |
| EP-2274411-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL LLC (US) | 2011-01-19 | — | — | EP | claimed |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2011-01-06 | — | — | US | claimed |
| EP-2249641-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | Flaxan GmbH & Co. KG (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009126320-A1 | XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS | BETAL, LLC (US) | 2009-10-15 | — | — | WO | claimed |
| WO-2009108379-A1 | NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES | FLAXAN GMBH & CO. KG (US) | 2009-09-03 | — | — | WO | claimed |
| US-20090209654-A1 | Prenylflavonoid Formulations | BIOACTIVES, INC. | 2009-08-20 | — | — | US | claimed |
| WO-2008089137-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1909584-A2 | PRENYLFLAVONOID FORMULATIONS | Bioactives, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070218155-A1 | Methods and compositions for treating dyslipidaemia | BIOACTIVES, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2007016578-A2 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| CN-118666663-A | Novel chalcone compound and preparation method, pharmaceutical composition and application thereof | 中日友好医院(中日友好临床医学研究所) | 2024-09-20 | — | — | CN | disclosed |
| US-20070218155-A1 | Methods and compositions for treating dyslipidaemia | BIOACTIVES, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283098-A1 | PRENYLATED CHALCONE FORMULATION FOR THE TREATMENT OF BEES | API5, CYP51A1, CYP46A1 | ABCB1 233/4885PDPK1 969/4885TTR 2530/4885 |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | TP53, CYP46A1, HPGD | ABCB1 295/4885PDPK1 1418/4885TTR 542/4885 |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | ABCB1 3546/4885PDPK1 1218/4885TTR 470/4885 |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | ABCB1 3546/4885PDPK1 1218/4885TTR 470/4885 |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | HMGB2, HMGB3, HPGDS | ABCB1 1531/4885PDPK1 2732/4885TTR 1767/4885 |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | NAPRT, NISCH, NAMPT | ABCB1 1868/4885PDPK1 3203/4885TTR 274/4885 |
| US-20090209654-A1 | Prenylflavonoid Formulations | TP53, CYP46A1, HPGD | ABCB1 295/4885PDPK1 1418/4885TTR 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.